Status:
RECRUITING
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
Lead Sponsor:
University Hospital, Bordeaux
Collaborating Sponsors:
University of Bordeaux
Conditions:
Multiple Sclerosis
Clinically Isolated Syndrome
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The study aims at identifying the type of B and CD4 T cell subsets with pathogenic properties in the different clinical forms of multiple sclerosis. This research might open new therapeutic approaches...
Detailed Description
Multiple sclerosis (MS) is a chronic autoimmune disease damaging the central nervous system (CNS). MS is categorized into several distinct forms according to clinical symptoms and medical examinations...
Eligibility Criteria
Inclusion
- male or female subjects ;
- Age ≥ 18 years;
- subjects with MS defined by 2010 revised McDonald criteria or presenting a clinical isolated syndrome;
- patients for which a blood draw and / or lumbar puncture to collect CSF is performed for diagnostic or therapeutic purpose;
- affiliated to an health insurance system;
- and who agree to participate in the study.
Exclusion
- Pregnant or breastfeeding women,
- patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent)
Key Trial Info
Start Date :
September 30 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2026
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04798651
Start Date
September 30 2021
End Date
September 1 2026
Last Update
February 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Bordeaux - service de neurologie
Bordeaux, France